Plasma fluphenazine and prolactin levels in schizophrenic patients during treatment with low and high doses of fluphenazine enanthate

1980 ◽  
Vol 71 (2) ◽  
pp. 131-136 ◽  
Author(s):  
D. Wiles ◽  
M. Franklin ◽  
S. J. Dencker ◽  
R. Johansson ◽  
L. Lundin ◽  
...  
Keyword(s):  
Schizophrenic Patients ◽  
Fluphenazine Enanthate ◽  
High Doses

Sulpiride and Haloperidol in Schizophrenia: A Double-blind Cross-over Study of Therapeutic Effect, Side Effects and Plasma Concentrations

1985 ◽  
Vol 147 (3) ◽  
pp. 283-288 ◽  
Author(s):  
Jes Gerlach ◽  
Kirsten Behnke ◽  
Jon Heltberg ◽  
Ebbe Munk-Andersen ◽  
Henrik Nielsen
Keyword(s):  
Side Effects ◽  
Plasma Concentrations ◽  
Clinical Effects ◽  
Median Dose ◽  
Double Blind ◽  
Day Range ◽  
Daily Dose ◽  
Schizophrenic Patients ◽  
High Doses ◽  
Therapeutic Profile

SummaryIn a double-blind cross-over trial, 20 chronic schizophrenic patients were treated with sulpiride and haloperidol in two 12-week periods. The final median dose of sulpiride was 2000 mg/day (range 800–3200) and of haloperidol 12 mg/day (range 6–24). Sulpiride had an antipsychotic effect and therapeutic profile not significantly different from that of haloperidol. In spite of the high doses of sulpiride, extrapyramidal side-effects were seen less frequently during the first four weeks of the sulpiride period than during the corresponding haloperidol period (P < 0.05), whereas autonomic side-effects were equally rare for both drugs. A positive correlation was found between daily dose and plasma concentration of both sulpiride (P < 0.001) and haloperidol (P < 0.05), but no correlation could be established between clinical effects and plasma levels of either neuroleptic.

A Controlled Trial of Fluphenazine Enanthate in Hospitalized Chronic Schizophrenics

1968 ◽  
Vol 114 (512) ◽  
pp. 837-841 ◽  
Author(s):  
Ijaz Haider
Keyword(s):  
Controlled Trial ◽  
Chronic Schizophrenics ◽  
Schizophrenic Patients ◽  
Fluphenazine Enanthate ◽  
Prescribed Medicines ◽  
Long Acting

The need for a long-acting phenothiazine has been long recognized, especially since it has been shown (Parkeset al., 1962; Rentonet al., 1963; Kline, 1964; Willcoxet al., 1965; Wilson and Enoch, 1967) that a high proportion of schizophrenic patients do not take their prescribed medicines.

Treatment with glutamatergic drugs in the resistant schizophrenia

2011 ◽  
Vol 26 (S2) ◽  
pp. 1447-1447
Author(s):  
R. Martínez de Velasco Soriano ◽  
F. Pando Velasco ◽  
M. Serrano Díaz de Otálora ◽  
P. Artieda Urrutia ◽  
C. Riaza Bermudo-Soriano
Keyword(s):  
Brain Development ◽  
Negative Symptoms ◽  
Clinical Manifestations ◽  
Normal Brain ◽  
Excitatory Neurotransmitter ◽  
Schizophrenic Patients ◽  
Neurodevelopmental Impairment ◽  
High Doses ◽  
Neurodevelopmental Hypothesis ◽  
Normal Brain Development

IntroductionThe neurodevelopmental hypothesis defends the existance of factors that would cause an early impairment on the normal brain development. The neurodegenerative hypothesis proposes the existance of later and progressive pathological phenomena, responsible of the appearance of clinical manifestations and changes on neuroimaging. Both hypotheses would be complementary. Neurodevelopment is completed during adolescence. Within this period, these deficts on executive functions would become apparent, reflecting a neurodevelopmental impairment. Glutamate is the main excitatory neurotransmitter, present throughout the normal postnatal brain development and maduration. In schizophrenic patients and unaffected relatives, a glutamatergic hypofunction has been found and so, an alteration of the dopaminergic mesocortical limbic and nigrostriatal pathways.ObjectivesUsage of molecules that are capable of reversing the glutamatergic hypofunction would be potentially benefitial for either positive or negative symptomathology in schizophrenia.MethodWe have performed a review of several clinical trials (on humans and animals) using glutamatergic drugs alone and combined with neuroleptics to diminish behavioural disturbances related to NMDA blockage.ResultsUsage of glycine binding site agonists (glycine, D- cicloserine, D-serine) has been proposed. D-serine is effective both as monotherapy and combined with neuroleptics. D-cicloserine is not effective on negative symptoms. Usage of high doses of oral glycine (30–60 mg a day) on its own has not shown any clinical change but there is an improvement on negative and positive symptoms if combined with neuroleptics.ConclusionNowadays, there is no glutamatergic agonist used in schizophrenia treatment. Out of the three previously mentioned drugs, only D-serine has shown some efficacy.

High doses of diazepam improve neuroleptic-resistant chronic schizophrenic patients

1983 ◽  
Vol 81 (1) ◽  
pp. 42-47 ◽  
Author(s):  
J. N. Nestoros ◽  
N. P. V. Nair ◽  
J. R. Pulman ◽  
G. Schwartz ◽  
D. Bloom
Keyword(s):  
Chronic Schizophrenic ◽  
Schizophrenic Patients ◽  
High Doses

Propranolol in Chronic Schizophrenia: A Controlled Study in Neuroleptic-Treated Patients

1980 ◽  
Vol 137 (2) ◽  
pp. 126-130 ◽  
Author(s):  
Leif H. Lindström ◽  
Eva Persson
Keyword(s):  
Rating Scale ◽  
Chronic Schizophrenia ◽  
Placebo Treatment ◽  
Controlled Study ◽  
Psychotic Symptoms ◽  
Double Blind ◽  
Schizophrenic Patients ◽  
Psychiatric Rating ◽  
Psychiatric Rating Scale ◽  
High Doses

The effect of propranolol at a dose level of 1,280–1,920 mg per day was studied with a double-blind crossover design in twelve chronic schizophrenics with persistent psychotic symptoms despite maintenance treatment with a depot neuroleptic. By use of a psychiatric rating scale (CPRS), an improvement was seen during the two week period of propranolol compared to placebo treatment in six patients, whereas three patients were unchanged and three deteriorated. The effect on total symptom scores for the whole group was significantly better after propranolol. The data indicate that propranolol in high doses has an antipsychotic effect in some schizophrenic patients when receiving neuroleptics.

Liquid-chromatographic assay of diazepam and its major metabolites in serum, and application to pharmacokinetic study of high doses of diazepam in schizophrenics.

1985 ◽  
Vol 31 (10) ◽  
pp. 1712-1715 ◽  
Author(s):  
K Tada ◽  
T Moroji ◽  
R Sekiguchi ◽  
H Motomura ◽  
T Noguchi
Keyword(s):  
Pharmacokinetic Study ◽  
High Performance ◽  
Limit Of Detection ◽  
Biologically Active ◽  
Active Metabolites ◽  
Analytical Recovery ◽  
Schizophrenic Patients ◽  
High Doses ◽  
Biologically Active Metabolites ◽  
Liquid Chromatographic

Abstract In this rapid, sensitive method for simultaneously determining diazepam and its biologically active metabolites--nordiazepam, oxazepam, and temazepam--in serum, 250 to 1000 microL of serum is extracted with ether and the extracted compounds are quantified by "high-performance" liquid chromatography on a Shimpack FLC-C8 microparticulate column. Absorbance of the effluent is monitored at 254 nm. The limit of detection in serum is about 10 micrograms/L for each drug. Analytical recovery of each drug added to the serum varied from 91 to 102% for oxazepam and temazepam, from 82 to 99% for nordiazepam and diazepam. Within-day and between-day CVs ranged from 2 to 5% for oxazepam and temazepam, and from 2 to 7% for nordiazepam and diazepam. We also report results on using this assay in a pharmacokinetic study of high doses of diazepam used to treat chronic schizophrenic patients.

Long-Acting Phenothiazines in the Prevention of Relapse of Schizophrenic Patients

1973 ◽  
Vol 18 (3) ◽  
pp. 235-237 ◽  
Author(s):  
John Denham ◽  
Leslie Adamson
Keyword(s):  
Readmission Rate ◽  
Community Care ◽  
Continuous Treatment ◽  
Major Advance ◽  
Duration Of Hospital Stay ◽  
Care Services ◽  
Schizophrenic Patients ◽  
Fluphenazine Enanthate ◽  
Long Acting ◽  
Prevention Of Relapse

The development of the depot fluphenazine preparations has been a major advance in the drug treatment of schizophrenia, ensuring continuous medication and stimulating the development of adequate community care services, resulting in significant reduction of relapse and readmission. This report compares the incidence of readmissions and the duration of hospital stay in a group of chronic schizophrenic patients who had first received oral medication and then long-acting injectable fluphenazine enanthate and decanoate over identical periods of time. A percentage of 93.3 of the subjects were maintained on continuous treatment for twelve to forty months. The readmission rate was reduced from 191 to 50, and the time spent in hospital from 8,713 to 1,335 days.

P.3.c.040 Treatment adherence and tolerability of high doses of risperidone longacting injectable in severe schizophrenic patients

2010 ◽  
Vol 20 ◽  
pp. S481
Author(s):  
J.j. Fernandez-Miranda ◽  
I. Gancedo-Alvarez ◽  
M. Redondo-Alvarez ◽  
V. Carames-Garcia ◽  
A. Sanchez-Garcia
Keyword(s):  
Treatment Adherence ◽  
Schizophrenic Patients ◽  
High Doses

High doses of fluphenazine enanthate in schizophrenia: A CONTROLLED STUDY

1978 ◽  
Vol 57 (5) ◽  
pp. 405-414 ◽  
Author(s):  
S. J. Dencker ◽  
R. Johansson ◽  
L. Lundin ◽  
U. Malm
Keyword(s):  
Controlled Study ◽  
Fluphenazine Enanthate ◽  
High Doses
Sign in / Sign up

Export Citation Format

Share Document